Update on IL-17 Inhibitors for Psoriasis

Abstract

Psoriasis is a common chronic, inflammatory skin condition. The pathogenesis of psoriasis involves many cytokines in the IL-17 family and their subsequent signaling cascade; therefore, IL-17 inhibitors may have utility in the treatment of psoriasis. This review aims to evaluate the efficacy and safety of IL-17 inhibitors and their emerging role as a therapeutic option for patients with psoriasis. In multiple phase III clinical trials, IL-17 inhibitors were more efficacious than placebo or slightly more efficacious in comparisons to many other systemic and biologic treatments. Overall, IL-17 inhibitors have a fairly mild side effect profile for use in psoriasis. One of the more severe theoretical adverse events is the activation or reactivation of inflammatory bowel disease. Many long-term ongoing clinical trials have promising initial results. Data suggests IL-17 inhibitors are efficacious and safe for use in patients with psoriasis. Patient non-adherence to taking daily pills or failed therapy with older systemic agents may be indications for the use of IL-17 inhibitors in patients with psoriasis.